四川宏明博思药业有限公司成立于2013年，专注于原料药和制剂的生产。现有员工400余人，主要生产高端剂型如注射剂、冻干粉针剂、片剂和胶囊剂。宏明博思的冻干粉针制剂生产线已获得EU GMP，并通过巴西ANVISA现场检查。目前四川宏明博思冻干粉针制剂的多个产品在巴西、智利、秘鲁、危地马拉、泰国、菲律宾、马来西亚、南非、澳大利亚等开展注册中。Sichuan Omnis Pharmaceutical Co., Ltd. was established in 2013, focusing on the manufacture of FDFs and APIs, located in Sichuan Chengdu, China. It currently has more than 400 employees and mainly produces high-end dosage forms such as injections, lyophilized powder injections, tablets and capsules. Omnis has granted China/EU/ANVISA/PICs GMP for lyophilized powder injection line. Currently, multiple products of lyophilized powder injection are undergoing registration in Brazil, Chile, Peru, Guatemala, Thailand, the Philippines, Malaysia, South Africa, Australia, and other countries.
2013年1月，成都百裕金阁莱药业有限公司成立
Jan. 2013, Established Chengdu Baiyu Ginkgolide Pharmaceutical Co., Ltd
2013年12月，开工奠基
Dec. 2013, Groundbreaking
2018年3月，启动商业化生产
Mar. 2018, Launched commercial production
2018年4月，与ELC医药签署欧盟2个产品商务合同
Apr. 2018, Signed commercial contract with ELC Pharmaceutical for2 products in EU
2022年3月，通过欧盟认证现场检查
Mar. 2022, Passed the EU GMP certification on-site inspection
2022年8月，百裕金阁莱更名为四川宏明博思药业有限公司
Aug. 2022, Baiyu Ginkgolide changed its name to Sichuan Omnis Pharmaceutical Co. Ltd
2022年12月，四川生物医药集团与百裕制药签订战略协议
Dec. 2022, Biomedical Industrial Group signed a strategic agreement with Baiyu Pharmaceuticals
2023年1月-2月，取得宏明博思药品生产许可证产品批件、GMP认证
Jan.-Feb. 2023, Obtained the DML, product certificate, China GMP
2023年5月，取得欧盟认证证书通过巴西认证现场审计检查
May 2023, Granted the EU GMP and passed the on-site audit inspection by ANVISA
2023年7月，取得ANVISA GMP
Jul. 2023, Granted the ANVISA GMP
